Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 12/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.60 |
| ▸ | PARP1 | P09874 | 10/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497483 | 0.86 | KDM4E (0.46) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4508581 | 0.85 | PIM1 (0.50) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4511031 | 0.84 | TNKS (0.62) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4508759 | 0.84 | TNKS (0.45) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4498837 | 0.83 | KDM4E (0.50) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4503194 | 0.82 | GUSB (0.47) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4503454 | 0.81 | IKBKB (0.45) | TNKSTNKS2PARP1KDM4EALDH1A1 | |
| SCHEMBL4511616 | 0.80 | ALDH1A1 (0.68) | TNKSTNKS2PARP1PARP2KDM4E | |
| SCHEMBL4493931 | 0.80 | PARP1 (0.52) | PARP1KDM4EALDH1A1MAPTPDE10A | |
| SCHEMBL4497605 | 0.79 | TNKS (0.61) | TNKSTNKS2PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | claimed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | TNKS 116/4885TNKS2 78/4885PARP1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.